Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

TW-37

For research use only.

Catalog No.S1121

40 publications

TW-37 Chemical Structure

CAS No. 877877-35-5

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 1192.13 In stock
RMB 1310.31 In stock
RMB 5570.25 In stock
RMB 12121.20 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's TW-37 has been cited by 40 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
In vitro

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell M1\vTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWTH[o86UW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYhdk1? MX3TRW5ITVJ?
human Ca9-22 cell M4H0T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFHvOJVKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDJibl2= MmSxV2FPT0WU
human CHL-1 cell NGTTTJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlvvTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlkhdk1? MYnTRW5ITVJ?
human A549 cell Mmj3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDpRZpKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE4xQSCwTR?= NECybZFUSU6JRWK=
human RKO cell M1jnVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXHjNYVbUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4yPyCwTR?= NVS1U2dQW0GQR1XS
human GCIY cell M4naN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW\IWIpoUW6qaXLpeIlwdiCxZjDoeY1idiCJQ1nZJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlAvQDNibl2= MULTRW5ITVJ?
human BHT-101 cell NV3mbW93T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHWwTHJKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOS56MzDuUS=> MVvTRW5ITVJ?
human Hs-578-T cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVj6N2ZoUW6qaXLpeIlwdiCxZjDoeY1idiCKcz21O|guXCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ|LkW5JI5O NEDGZ4hUSU6JRWK=
human SK-UT-1 cell M1vxO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnzOTY5pcWKrdHnvckBw\iCqdX3hckBUUy2XVD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvPjhibl2= Mn\jV2FPT0WU
human NB7 cell NG\jW2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnfKTY5pcWKrdHnvckBw\iCqdX3hckBPSjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{OT6yPEBvVQ>? MWPTRW5ITVJ?
human YKG-1 cell NHj6PFNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkTUTY5pcWKrdHnvckBw\iCqdX3hckB[U0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK5Mlc3KG6P M4PCfnNCVkeHUh?=
human HuH-7 cell M{fYdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJGh2UC15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{KuPFIhdk1? MVXTRW5ITVJ?
human SAS cell MmnQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXkO3ZKdmirYnn0bY9vKG:oIHj1cYFvKFODUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOzMlE5KG6P Ml:2V2FPT0WU
human UACC-62 cell Mn3RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXvJPYVvUW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVYzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwM{Wgcm0> NVXZPYFLW0GQR1XS
human AGS cell NUnnV3pCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{ntemlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{euOVMhdk1? MnzUV2FPT0WU
human SK-MEL-30 cell NF;QS49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3v2NGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzdwOUegcm0> NHTYWFdUSU6JRWK=
human A427 cell NWLSUItWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlXOTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NESuOlkhdk1? MU\TRW5ITVJ?
human DU-145 cell MlPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWyMlE{KG6P MlX6V2FPT0WU
human HCT-116 cell MmLpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUL2S2dqUW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTJwNk[gcm0> MmXaV2FPT0WU
human A673 cell NUTVU5QzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NE\Dd4tKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21N{45PSCwTR?= MWXTRW5ITVJ?
human SF126 cell M{\JfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUeuNFchdk1? NXTBenpWW0GQR1XS
human SW872 cell MoDlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2PDUWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21PE46KG6P MWPTRW5ITVJ?
human NCI-H1581 cell M2TPWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmTUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1PFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Py54NDDuUS=> MlHQV2FPT0WU
human SK-MEL-5 cell NX;4W25DT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4i0PWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QS5{NTDuUS=> NV3XO2I5W0GQR1XS
human CP50-MEL-B cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGNRPTBvTVXMMWIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QS53OTDuUS=> MofiV2FPT0WU
human YH-13 cell NHi5e3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkX0TY5pcWKrdHnvckBw\iCqdX3hckB[UC1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUewMlU6KG6P NYPIdpczW0GQR1XS
human LXF-289 cell M3;TXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml;1TY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|IvQDVibl2= NFfV[HdUSU6JRWK=
human MC-IXC cell NF3OeZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{nJZmlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|UvOzNibl2= NH3O[Y1USU6JRWK=
human NB14 cell M1TyTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF;5OZZKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Ok41PSCwTR?= NEi1Z|BUSU6JRWK=
human HEC-1 cell NVH2XYM4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXrWOI1HUW6qaXLpeIlwdiCxZjDoeY1idiCKRVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgyNjN5IH7N M{nyOXNCVkeHUh?=
human U-87-MG cell NYjIV4dwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn3qTY5pcWKrdHnvckBw\iCqdX3hckBWNTh5LV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFIvOjRibl2= M2K2OHNCVkeHUh?=
human HOS cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NILodlhKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi0MlcyKG6P MWTTRW5ITVJ?
human HUTU-80 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYHJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24O{4xOSCwTR?= NWmxfXY5W0GQR1XS
human A375 cell NF73emtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV73bGcxUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFgvQDNibl2= NFf6PJRUSU6JRWK=
human A204 cell M2XsTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVnJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Nz64OEBvVQ>? M4PmXXNCVkeHUh?=
human GB-1 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWHQVVNUUW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVgvPjlibl2= MYjTRW5ITVJ?
human MDA-MB-231 cell MnzXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFroVoVKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0zOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGwPFA4KM7:TR?= NV:wfGFiW0GQR1XS
human SW982 cell NEO0U5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUHIdFNlUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTFyNzFOwG0> MUfTRW5ITVJ?
human SW756 cell NYrte2RYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV;3W4NiUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF{M{[g{txO NEexN2RUSU6JRWK=
human MG-63 cell NGHpSWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVI1QCEQvF2= NF\uRWdUSU6JRWK=
human Daoy cell NF;nNGNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU\QfG1GUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPDB5MzFOwG0> MWTTRW5ITVJ?
human MDA-MB-453 cell Ml32S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1T1R2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ2OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUWxPFgh|ryP NWTjdo02W0GQR1XS
human HT-144 cell NXTweGQ4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF2NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVUzODFizszN M2rLbnNCVkeHUh?=
human LoVo cell Mn7ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUC5c|NvUW6qaXLpeIlwdiCxZjDoeY1idiCOb2\vJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPjB7MzFOwG0> M{jJO3NCVkeHUh?=
human NY cell M1eyVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfDTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUe3OlIh|ryP M2jzN3NCVkeHUh?=
human SW1783 cell Mny2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2PSUGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{izJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOTNyMTFOwG0> NXK3XYp1W0GQR1XS
human A2780 cell NFn1T|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2LM[mlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyQDR4IN88US=> NXXQRXJ4W0GQR1XS
human MDA-MB-361 cell M2rPbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ{NkSg{txO M4rhUXNCVkeHUh?=
human RPMI-2650 cell MofRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3SNnJsUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVI3PTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKzPFMyKM7:TR?= NIfFcYZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

Protocol

Kinase Assay:[1]
- Collapse

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
Cell Research:[2]
- Collapse
  • Cell lines: HDMECs
  • Concentrations: 0 - 100 μM
  • Incubation Time: 96 hours
  • Method: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • Dosages: ~40 mg/kg
  • Administration: Administered via i.v. or i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 573.7
Formula

C33H35NO6S

CAS No. 877877-35-5
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID